Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

219

Participants

Timeline

Start Date

July 1, 2009

Primary Completion Date

March 4, 2015

Study Completion Date

March 4, 2015

Conditions
Myelofibrosis
Interventions
DRUG

Ruxolitinib

5 mg tablets packaged as 60-count in high-density polyethylene bottles

DRUG

Best Available Therapy (BAT)

Prescribing and usage per respective package inserts

Trial Locations (61)

1081

Novartis Investigative Site, Amsterdam

1200

Novartis Investigative Site, Brussels

2020

Novartis Investigative Site, Antwerp

2060

Novartis Investigative Site, Antwerp

3000

Novartis Investigative Site, Leuven

3500

Novartis Investigative Site, Hasselt

4010

Novartis Investigative Site, Linz

5020

Novartis Investigative Site, Salzburg

5530

Novartis Investigative Site, Yvoir

5800

Novartis Investigative Site, Maastricht

6020

Novartis Investigative Site, Innsbruck

7100

Novartis Investigative Site, La Louvière

8000

Novartis Investigative Site, Bruges

8500

Novartis Investigative Site, Kortrijk

8800

Novartis Investigative Site, Roeselare

10043

Novartis Investigative Site, Orbassano

13273

Novartis Investigative Site, Marseille

13353

Novartis Investigative Site, Berlin

14033

Novartis Investigative Site, Caen

20162

Novartis Investigative Site, Milan

20900

Novartis Investigative Site, Monza

27100

Novartis Investigative Site, Pavia

Novartis Investigative Site, Pavia

28222

Novartis Investigative Site, Majadahonda

30029

Novartis Investigative Site, Nîmes

31059

Novartis Investigative Site, Toulouse

33600

Novartis Investigative Site, Pessac

38043

Novartis Investigative Site, Grenoble

39120

Novartis Investigative Site, Magdeburg

46010

Novartis Investigative Site, Valencia

48149

Novartis Investigative Site, Münster

50134

Novartis Investigative Site, Florence

50937

Novartis Investigative Site, Cologne

55131

Novartis Investigative Site, Mainz

59037

Novartis Investigative Site, Lille

60590

Novartis Investigative Site, Frankfurt/M

62307

Novartis Investigative Site, Lens

67091

Novartis Investigative Site, Strasbourg

69437

Novartis Investigative Site, Lyon

70376

Novartis Investigative Site, Stuttgart

72076

Novartis Investigative Site, Tübingen

75010

Novartis Investigative Site, Paris

75012

Novartis Investigative Site, Paris

75014

Novartis Investigative Site, Paris

80054

Novartis Investigative Site, Amiens

86021

Novartis Investigative Site, Poitiers

89081

Novartis Investigative Site, Ulm

94805

Novartis Investigative Site, Villejuif

A-1090

Novartis Investigative Site, Vienna

F-35043

Novartis Investigative Site, Rennes

9713 GZ

Novartis Investigative Site, Groningen

6500 MB

Novartis Investigative Site, Nijmegen

3015 CE

Novartis Investigative Site, Rotterdam

2545 CH

Novartis Investigative Site, The Hague

08036

Novartis Investigative Site, Barcelona

SE-413 45

Novartis Investigative Site, Gothenburg

SE-118 83

Novartis Investigative Site, Stockholm

BT9 7AB

Novartis Investigative Site, Belfast

CB2 2QQ

Novartis Investigative Site, Cambridge

SE1 9RT

Novartis Investigative Site, London

OX37LJ

Novartis Investigative Site, Oxford

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY